| Lung Cancer |
1 |
1 |
| Non-Small Cell Lung Cancer |
0 |
0.99 |
| Skin Cancer |
0 |
0.75 |
| Biologic Therapy |
0 |
0.69 |
| Head and Neck Cancer |
0 |
0.61 |
| Tumor |
0 |
0.6 |
| Breast Cancer |
0 |
0.55 |
| Genomic Medicine |
0 |
0.52 |
| Small Cell Lung Cancer |
0 |
0.52 |
| Cancer |
0 |
0.48 |
| Lung |
0 |
0.42 |
| Melanoma |
0 |
0.31 |
| Chemotherapy |
0 |
0.98 |
| Immunotherapy |
0 |
0.18 |
| Patient Safety |
0 |
0.13 |
| Disease Recurrence |
0 |
0.12 |
| Epidermal Growth Factor Receptor |
0 |
0.12 |
| Adverse Effects |
0 |
0.06 |
| Anaplastic Lymphoma Kinase |
0 |
0.06 |
| Brachial |
0 |
0.06 |
| Breast |
0 |
0.06 |
| Central Nervous System |
0 |
0.06 |
| Cervical Region |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Perioperative Care |
0 |
0.06 |
| Platinum |
0 |
0.06 |